ArticlePharmaceutics2022
Novel Cocrystals of Vonoprazan: Machine Learning-Assisted Discovery.
Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 12 citations in OpenAlex.
- Rational High-Throughput Screening of Cocrystals: An Explainable Deep Learning Framework Based on Morgan Fingerprints and Cross-Attention.ACS physical chemistry Au · 2026Article
- From Crystal Structure to Dissolution Enhancement: Cocrystal Engineering of Resmetirom to Address Its Solubility Challenge.Pharmaceutical research · 2026Article
- Explainable Machine Learning for Efficient Cocrystal Prediction: Leveraging Morgan Fingerprints to Decode Local Structure-Cocrystal Formation Relationships.The journal of physical chemistry. A · 2026Article
- Nano Engineered Chitosan-Based Delivery System for Vonoprazan Fumarate for Enhanced Bioavailability: Fabrication and Evaluation.International journal of nanomedicine · 2026Article
- Comprehensive Investigation of Polymorphic Stability and Phase Transformation Kinetics in Tegoprazan.Pharmaceutics · 2025Article
- Graph Neural Networks with Multi-features for Predicting Cocrystals using APIs and Coformers Interactions.Current medicinal chemistry · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Vonoprazan (VPZ) is the first-in-class potassium-competitive acid blocker (P-CAB), and has many advantages over proton pump inhibitors (PPIs). It is administered as a fumarate salt for the treatment of acid-related diseases, including reflux esophagitis, gastric ulcer, and duodenal ulcer, and for eradication of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.